Table 3. . Persistence predictors in the use of anti-TNF agents after 6 and 12 months.

Variables	Anti-TNF – 6 months
HR crude	p-value	HR adjusted	p-value
Sex
Male	1		1
Female	2.08 (0.90–4.83)	0.087	2.42 (1.03–5.69)	0.043
Anti-TNF
Adalimumab	1		1
Etanercept	1.16 (0.46–2.96)	0.749	1.20 (0.48–3.07)	0.749
Infliximab	3.08 (1.15–8.20)	0.025	3.73 (1.38–10.11)	0.010
Age
Until 50 years	1		–	–
>50 years	0.47 (0.22–1.10)	0.086	–	–
Variables	Anti-TNF – 12 months
	HR crude	p-value	HR adjusted	p-value
Sex
Male	1		1
Female	2.23 (1.20–4.15)	0.011	2.65 (1.40–5.02)	0.003
Anti-TNF
Adalimumab	1		1
Etanercept	1.01 (0.52–2.01)	0.96	1.07 (0.54–2.12)	0.749
Infliximab	2.41 (1.11–5.21)	0.025	3.25 (1.47–7.21)	0.004
CRP
Until 5 mg/l	1		–	–
>5 mg/l	0.66 (0.36–1.21)	0.177	–	–
Rheumatoid factor
Negative	1		–	–
Positive	2.64 (1.03–6.77)	0.042	–	–

Only the variables with a p-value < 0.20 in the bivariate analysis were shown.

1 (reference category).

Bold: variables with significant results in the final model - multivariable analysis.

HR: Hazard ratio.